Pasar al contenido principal

DISECCIONANDO EL PAPEL DE NPC2 Y CD109, DOS NUEVOS EFECTORES DE METASTASIS, EN CANCER COLORRECTAL

PID2021-122227OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrated meta-analysis of colorectal cancer public proteomic datasets for biomarker discovery and validation

  • Robles, Javier
  • Prakash, Ananth
  • Vizcaíno, Juan Antonio
  • Casal, J. Ignacio
24 p.-8 fig.-2 tab., The cancer biomarker field has been an object of thorough investigation in the last decades. Despite this, colorectal cancer (CRC) heterogeneity makes it challenging to identify and validate effective prognostic biomarkers for patient classification according to outcome and treatment response. Although a massive amount of proteomics data has been deposited in public data repositories, this rich source of information is vastly underused. Here, we attempted to reuse public proteomics datasets with two main objectives: i) to generate hypotheses (detection of biomarkers) for their posterior/downstream validation, and (ii) to validate, using an orthogonal approach, a previously described biomarker panel. Twelve CRC public proteomics datasets (mostly from the PRIDE database) were re-analysed and integrated to create a landscape of protein expression. Samples from both solid and liquid biopsies were included in the reanalysis. Integrating this data with survival annotation data, we have validated in silico a six-gene signature for CRC classification at the protein level, and identified five new blood-detectable biomarkers (CD14, PPIA, MRC2, PRDX1, and TXNDC5) associated with CRC prognosis. The prognostic value of these blood-derived proteins was confirmed using additional public datasets, supporting their potential clinical value. As a conclusion, this proof-of-the-concept study demonstrates the value of re-using public proteomics datasets as the basis to create a useful resource for biomarker discovery and validation. The protein expression data has been made available in the public resource Expression Atlas., This project was supported by grants RTI2018-095055-B-I00, PID2021-122227OB-I00 and PDC2022-133056-I00 from the Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033) using Next Generation EU/PRTR funds to JIC, and BBSRC grant number BB/T019670/1 and EMBL core funding to JAV. JR was supported by IND2019/BMD-17153 fellowship of the Comunidad de Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype

  • Bartolomé, Rubén Álvaro
  • Pintado-Berninches, Laura
  • Martin-Regalado, Ángela
  • Robles, Javier
  • Calvo-López, Tania
  • Ortega-Zapero, Marina
  • Llorente-Sáez, Celia
  • Boukich, Issam
  • Fernandez-Aceñero, M. Jesús
  • Casal, J. Ignacio
17 p.-7 fig., Background: Cadherin-17 (CDH17), a marker of differentiation in intestinal cells, binds and activates α2β1 integrin to promote cell adhesion and proliferation in colorectal cancer (CRC) metastasis. Furthermore, CDH17 associates with p120- and β-catenin in a manner yet to be fully elucidated. In this report, we explored the molecular mediators involved in this association, their contribution to CRC dissemination and potential therapeutic implications., Methods: Proteomic and confocal analyses were employed to identify and validate CDH17 interactors. Functional characterization involved the study of proliferation, migration, and invasion in cell lines representative of various phenotypes. Immunohistochemistry was conducted on CRC tissue microarrays (TMA). In vivo animal experiments were carried out for metastatic studies., Results: We found that desmocollin-1 (DSC1), a desmosomal cadherin, interacts with CDH17 via its extracellular domain. DSC1 depletion led to increased or decreased invasion in CRC cells displaying epithelial or mesenchymal phenotype, respectively, in a process mediated by the association with p120-catenin. Down-regulation of DSC1 resulted in an increased expression of p120-catenin isoform 1 in epithelial cells or a shift in cellular location in mesenchymal cells. Opposite results were observed after forced expression of CDH17. DSC1 is highly expressed in budding cells at the leading edge of the tumor and associates with poor prognosis in the stem-like, mesenchymal CRC subtypes, while correlates with a more favorable prognosis in the less-aggressive subtypes. In vivo experiments demonstrated that DSC1 silencing reduced tumor growth, liver homing, and metastasis in CRC mesenchymal cells. Furthermore, a synthetic peptide derived from CDH17, containing the NLV motif, effectively inhibited invasion and liver homing in vivo, opening up new possibilities for the development of novel therapies focused on desmosomal cadherins., Conclusions: These findings shed light on the multifaceted roles of CDH17, DSC1, and p120-catenin in CRC metastasis, offering insights into potential therapeutic interventions for targeting desmosomal cadherins in poorly-differentiated carcinomas., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Laura Pintado-Berninches was supported by a Margarita Salas contract (CA1/RSUE/2021–00208) from the Ministry of Universities (Spain). Angela Martín-Regalado was supported by a FPU fellowship (FPU18/05766-MEFP). Javier Robles and Issam Boukich were supported by IND2019/BMD-17153 and IND2022/BMD-23554 fellowship grants of the Comunidad de Madrid. This project was supported by grants RTI2018-095055-B-I00 and PID2021-122227OB-I00 from the MCIN/AEI/https://doi.org/10.13039/501100011033 and by the grant PMPTA22/00108 from Instituto de Salud Carlos III using Next Generation EU/PRTR funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells

  • Bartolomé, Rubén Álvaro
  • Pintado-Berninches, Laura
  • Robles, Javier
  • Calvo-López, Tania
  • Boukich, Issam
  • Otero-Núñez, Pablo
  • González-Sancho, José Manuel
  • Casal, J. Ignacio
13 p.-8 fig., Cadherin 17 (CDH17) plays a crucial role in the metastatic progression of colorectal cancer (CRC) through its interaction with α2β1 integrin and desmocollin 1. To further elucidate the molecular mechanisms involving CDH17 functions in CRC, we examined global expression alterations following CDH17 silencing in various metastatic cell lines. Loss of CDH17 resulted in a marked down-regulation of the intestinal cancer stem cell (CSC) marker LGR5, leading to the inhibition of Wnt/β-catenin signaling, suppression of pluripotency genes such as MYC, and a subsequent reduction in stemness properties. Treatment with CDH17/integrin blocking antibodies produced similar effects, decreasing both, LGR5 expression and Wnt signaling. CDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5. Consequently, the loss of CDH17 increased sensitivity to 5-FU, irinotecan, oxidative stress and anoikis in CRC cells. Notably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival. Pharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models. In conclusion, CDH17 plays a crucial role in maintaining colorectal cancer cell stemness and chemoresistance via LGR5/Wnt/MYC signaling and SLC38A5 expression. These findings underscore the therapeutic potential of CDH17 targeting in metastatic CRC, and support the use of amiloride for inhibiting liver metastasis., Laura Pintado-Berninches was supported by a Margarita Salas contract (CA1/RSUE/2021-00208) from the Ministry of Universities (Spain). Javier Robles and Issam Boukich were supported by IND2019/BMD-17153 and IND2022/BMD-23554 fellowship grants of the Comunidad de Madrid, respectively. This project was supported by the grants PID2021-122227OB-I00 of the Ministerio de Ciencia e Innovación (Spain) and PMPTA22/00108 from Instituto de Salud Carlos III using Next Generation EU/PRTR funds from the MCIN/AEI/10.13039/501100011033, and grant S2022/BMD-7212 funded by the Comunidad de Madrid, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The emerging role of human transmembrane RGD-based counter-receptors of integrins in health and disease

  • Cabañas, Carlos
  • Rossi, Elisa
  • Bartolomé, Rubén Álvaro
  • Doberstein, Kai
  • Altevogt, Peter
  • Casal, J. Ignacio
  • Bernabéu, Carmelo
Most of the canonical Arg-Gly-Asp (RGD)-containing integrin ligands are extracellular matrix proteins, such as fibronectin, vitronectin and fibrinogen, which regulate cell-ECM adhesion processes. However, during the last years, several reports have demonstrated the existence of non-canonical RGD-containing integrin ligands that are cell surface transmembrane proteins. At variance with the canonical extracellular matrix integrin ligands, the RGD-containing cell surface integrin ligands are involved in cell-cell adhesion processes and function as "integrin counter-receptors". We propose in this review grouping these transmembrane proteins, which include endoglin, cadherin-5, cadherin-6, cadherin-17, ADAM15, and L1CAM, under the newly coined acronym RGD-ICRs (RGD-containing Integrin Counter-Receptors). We present and discuss the structure of RGD-ICRs, their RGD-based interactions with integrins, the specific signaling pathways triggered in different cell types, as well as their pathophysiological involvement. It can be postulated that RGD-ICRs constitute an emerging group of non-canonical RGD-based integrin counter-receptors. In spite of being encoded by different and independent genes and involved in different pathophysiological processes, all of them appear to have undergone a strong evolutionary convergence in order to acquire the same functional capacity to bind integrins via the RGD motif. Importantly, these RGD-ICRs are also emerging as novel biomarkers and therapeutic targets, with promising clinical potential in a wide array of pathologies., C.C. was supported by grant no. PID2021-123199OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) (MCIN/AEI/https://doi.org/10.13039/501100011033) and by the European Union. The CBM-SO is a \u201CSevero Ochoa Center of Excellence\u201D (grant no. CEX2021-001154-S) funded by MICIN/AEI/https://doi.org/10.13039/501100011033 and receives an institutional grant from the Fundaci\u00F3n Ram\u00F3n Areces. J.I.C. was supported by grant nos. PID2021-122227OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) and PMPTA22/00108 from the Instituto de Salud Carlos III using Next Generation EU/PRTR funds from the MCIN/AEI/https://doi.org/10.13039/501100011033. C.B. was supported by the Consejo Superior de Investigaciones Cient\u00EDficas (CSIC, Spain) (grant no. 201920E022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD109 Drives Stemness and Chemoresistance in Colorectal Cancer via LRRC8A/AKAP12/PKCα-Mediated STAT3 Activation and WNT Signaling

  • Bartolomé, Rubén Álvaro
  • Calvo-López, Tania
  • Otero-Núñez, Pablo
  • Estaras, María
  • Fernández-Barral, Asunción
  • Barbáchano, Antonio
  • Boukich, Issam
  • Cuerda-López, María
  • Fernández-Aceñero, Mª Jesús
  • Rodríguez-Urquirizar, Gorane
  • Mariscal-Casero, Ana
  • Padilla-Blanco, Miguel
  • Montoya, María
  • O'Loghlen, Ana
  • Fernández-Fernández, José M
  • Gonzalez-Sancho, Jose Manuel
  • Casal, J Ignacio
Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, with a poor survival rate at the metastatic stage. Here, we identify CD109-a negative regulator of TGFβ signaling-as a key driver of stemness and drug resistance through modulation of Wnt signaling in advanced CRC. CD109 expression strongly correlates with TGFβ levels in patient tumors and is enriched in the aggressive CRIS-B subtype, where it associates with poor clinical outcome. CD109 silencing reduced STAT3 phosphorylation and cell proliferation, without affecting migration or invasion. Moreover, global expression analysis revealed downregulation of various hallmarks of cancer stemness (i.e. LGR5 expression), together with increased TGFβ signaling and cellular senescence. Mechanistically, CD109 interacts with LRRC8A, a subunit of the volume-regulated anion channel (VRAC), which associates with AKAP12 to activate PKCα and promote STAT3 phosphorylation. This CD109/LRRC8A/AKAP12/PKCα axis sustains Wnt signaling, stemness, and drug resistance. Consistently, co-expression of CD109/LRRC8A/AKAP12 correlates with poor prognosis in CRC patients. Genetic or pharmacological disruption of this CD109/LRRC8A/AKAP12/PKCα axis impaired STAT3 signaling, reduced LGR5 expression and Wnt signaling, and sensitized cells to chemotherapy. In vivo, CD109 or LRRC8A knockdown significantly impaired liver homing and metastatic colonization in mouse models, showing stronger effects in Swiss nude mice than in highly immunodeficient NSG mice. Collectively, these findings support CD109 as a central regulator for STAT3-driven stemness and chemoresistance in advanced CRC, via the LRRC8A/AKAP12/PKCα axis, and highlight its potential value as a therapeutic target in metastatic disease., PON was supported by a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU) (Spain). IB and MC were supported by IND2022/BMD-23554 and IND2024/ BMD-34329 fellowship grants of the Comunidad de Madrid. AMC was funded by a PhD fellowship Ramon Areces (BTVP25S22277). JMFF´s lab was funded by the Spanish Ministry of Science and Innovation (MCIN)/State Research Agency (AEI, Agencia Estatal de Investigación)/10.13039/ 501100011033/, and FEDER Funds (Fondo Europeo de Desarrollo Regional) (grant PID2022-136546OB-I00 to J.M.F-F); “Unidad de Excelencia María de Maeztu” CEX2024-001431-M, funded by MICIU/AEI/ 10.13039/501100011033. AO’s lab was supported by projects CNS2022-135134 and PID2021-125656OB-I00 financed by MICIU/AEI/10.13039/501100011033, 10.13039/501100011033 and by project SenesceX S2022/BMD-7393 financed by the Comunidad de Madrid. JIC´s lab was supported by grants PID2021- 122227OB-I00 and PID2024-156301OB-I00 (MICIU) with funds MCIN/AEI/10.13039/501100011033 and “Next-Generation EU”/PRTR, and grant S2022/BMD-7212 funded by the Comunidad de Madrid (Spain). Ethics approval and consent to participate The collection of patient-derived samples for, Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Sistemas de cultivo - Cultivos 3D - organoides
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Papel de las cadherinas RGD en metástasis y búsqueda de nuevos biomarcadores pronósticos en cáncer colorrectal

  • Robles Sebastián, Javier
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología. Fecha de Lectura: 21-02-2024, [EN] Cancer is one of the major public health problems worldwide. Specifically, metastasis is responsible for more than 90% of cancer-related deaths. This Doctoral Thesis focused on the study of three types of cancer: colorectal cancer (CRC), ovarian cancer, and kidney cancer. In all of these, metastasis plays a crucial role in the patient's prognosis, as the spread of the primary tumor leads to a drastic decrease in survival. Therefore, it is of vital importance to identify new targets and develop new therapies that can inhibit metastasis. Additionally, in the case of CRC, there is an added difficulty due to its molecular and clinical heterogeneity, which complicates clinical decision-making and the selection of optimal treatment, especially in stages II and III. Hence, there is a need to develop new prognostic tools to assess the risk associated with each tumor for more personalized precision medicine. The objectives of the Doctoral Thesis focused on i) establishing the role of cadherin-6 (CDH6) and cadherin-17 (CDH17) in various tumor metastases, and ii) developing new prognostic tools in CRC. Previous studies on CDH17 in CRC and VE-cadherin in breast cancer and melanoma have shown that cadherins with an RGD motif (RGD cadherins) are potential therapeutic targets useful for exerting an antimetastatic effect due to their association with integrin α2β1. In this Doctoral Thesis, the relevance of CDH6 was first studied in ovarian and kidney cancer, where it is overexpressed. Cell lines with different levels of CDH6 expression and integrins αIIbβ3 and α2β1 were used for this purpose. It was demonstrated that CDH6 can bind and activate both integrins. In αIIbβ3-positive cells, CDH6 preferably binds to this integrin, but in αIIbβ3-negative lines, it can also associate with α2β1. Furthermore, a cross-interaction or crosstalk between both integrins was observed, where the activation of αIIbβ3 is a prerequisite for the activation of α2β1. The interaction of CDH6 with these integrins leads to an increase in prometastatic cellular capabilities such as proliferation, adhesion, migration, and invasion, which can be blocked with monoclonal antibodies or inhibitors of integrin αIIbβ3. On the other hand, the relevance of CDH17 in CRC metastasis was analyzed by stable silencing in the KM12SM and SW620 cell lines. It was demonstrated that the loss of CDH17 expression leads to a decrease in the LGR5 receptor and Wnt/β-catenin pathway activation. This results in a decrease in proliferative capacity and stem cell characteristics in tumor cells. The silencing of CDH17 also caused alterations in the epithelial-mesenchymal transition and the molecular basis of the circadian rhythm. Finally, it was observed that both CDH17 and E-cadherin can translocate to the nucleus. Secondly, to address the issue of CRC heterogeneity, a prognostic signature based on a panel of six biomarkers was developed from a proteomic analysis comparing the secretome of highly and poorly metastatic cell lines. This signature, called SEC6 and composed of the genes BMP1, CD109, IGFBP3, LTBP1, NPC2, and PSAP, proved effective in segregating stage II and III patients into high and low-risk categories. Patients classified as high-risk showed worse prognosis, a higher risk of relapse, and a poorer response to basic chemotherapy. Moreover, SEC6 also showed prognostic potential in other digestive cancers such as stomach, pancreas, and liver cancer. Finally, in collaboration with EMBL-EBI, another approach based on the reuse of proteomic data was conducted. Despite the generation and deposition of a large amount of proteomic data from CRC samples in public repositories over the years, this information has not been as widely used as transcriptomic data. This is mainly due to the difficulty in integrating data and the lower annotation of samples in repositories. In this Doctoral Thesis, a meta-study was conducted, including public datasets containing solid and liquid biopsy samples. This allowed the development of a protein expression map in CRC samples, enabling the comparison of protein expression between healthy tissue and tumor, evaluating its association with prognosis, and examining potential detection in liquid biopsies. This meta-study was applied in the validation and discovery of biomarkers, confirming the potential of SEC6 at the protein level and identifying five new potentially detectable prognostic biomarkers in serum (CD14, MRC2, PPIA, PRDX1, and TXNDC5). In conclusion, this Doctoral Thesis addresses two areas of great interest in cancer research: the inhibition of metastasis and the discovery of new prognostic biomarkers. Regarding metastasis, the potential of CDH6 as an antimetastatic target in ovarian and kidney cancer was demonstrated. Furthermore, the key involvement of CDH17 in hepatic metastasis of CRC was reinforced. In the field of biomarkers, the prognostic signature SEC6 was developed and validated, and a metastudy using proteomic datasets contributed to the discovery and validation of biomarkers, [ES] El cáncer es uno de los mayores problemas de salud pública en el mundo. Concretamente, la metástasis es causante de más del 90% de los fallecimientos debido a cáncer. En esta Tesis Doctoral se estudiaron tres tipos de cáncer: cáncer colorrectal (CCR), cáncer de ovario y cáncer de riñón. En todos ellos, la metástasis juega un papel trascendental en el pronóstico del paciente ya que la diseminación del tumor primario conlleva un descenso drástico de la supervivencia. Eso hace de vital importancia la identificación de nuevas dianas y el desarrollo de nuevas terapias que puedan inhibir la metástasis. Además, en el caso particular de CCR, existe una dificultad añadida debido a su gran heterogeneidad molecular y clínica, que dificulta la toma de decisiones clínicas y la selección del tratamiento óptimo, especialmente en los estadios II y III. Por ello, es necesario desarrollar nuevas herramientas pronósticas que permitan evaluar el riesgo asociado a cada tumor para aplicar una medicina de precisión más personalizada. Los objetivos de la Tesis Doctoral se centraron en i) establecer el papel de cadherina-6 (CDH6) y cadherina-17 (CDH17) en diversas metástasis tumorales y ii) desarrollar nuevas herramientas de pronóstico en CCR. Estudios previos centrados en CDH17 en CCR y en VE-cadherina en cáncer de mama y melanoma han demostrado que las cadherinas que presentan un motivo RGD (cadherinas RGD) son potenciales dianas terapeúticas de utilidad para ejercer un efecto antimetastásico debido a su asociación con la integrina α2β1. En esta Tesis Doctoral se estudió en primer lugar la relevancia de CDH6 en cáncer de ovario y cáncer de riñón, donde se encuentra sobreexpresada. Para ello, se emplearon líneas celulares con distintos niveles de expresión de CDH6 e integrinas αIIbβ3 y α2β1. Se demostró que CDH6 es capaz de unirse y activar ambas integrinas. En las células αIIbβ3 positivas, CDH6 se une preferentemente a esta integrina, pero en líneas αIIbβ3 negativas también puede asociarse con α2β1. Además, se observó una interacción cruzada o crosstalk entre ambas integrinas, de forma que la activación de αIIbβ3 es un prerrequisito para la activación de α2β1. La interacción de CDH6 con estas integrinas provoca un aumento de capacidades celulares prometástasicas como proliferación, adhesión, migración e invasión, las cuales pueden ser bloqueadas con anticuerpos monoclonales o inhibidores de la integrina αIIbβ3. Por otro lado, se analizó la relevancia de CDH17 en la metástasis de CCR mediante el silenciamiento estable en las líneas celulares KM12SM y SW620. Se demostró que la pérdida de expresión de CDH17 provoca un descenso del receptor LGR5 y de la activación de la vía Wnt/βcatenina. Esto desemboca en un descenso de la capacidad proliferativa y de las características de célula madre en las células tumorales. El silenciamiento de CDH17 también provocó una alteración en la transición epitelio-mesénquima y en las bases moleculares del ritmo circadiano. Finalmente, se observó que CDH17, y también E-cadherina, pueden translocarse al núcleo. En segundo lugar, para abordar el problema de la heterogeneidad del CCR, se desarrolló una firma pronóstica basada en un panel de seis biomarcadores identificados a partir de un análisis proteómico en el que se comparó el secretoma de líneas celulares alta y pobremente metastásicas. Esta firma, denominada SEC6 y compuesta por los genes BMP1, CD109, IGFBP3, LTBP1, NPC2 y PSAP, demostró ser efectiva para segregar los pacientes de estadios II y III en alto y bajo riesgo, de forma que los pacientes clasificados como pacientes de alto riesgo mostraron un peor pronóstico, un mayor riesgo de recaída y una peor respuesta a quimioterapia básica. Además, SEC6 también mostró potencial pronóstico en otros cánceres digestivos como cáncer de estómago, de páncreas y de hígado. Por último, en colaboración con el EMBL-EBI, se llevó a cabo otra aproximación basada en la reutilización de datos de proteómica. Aunque a lo largo de los años se han generado y depositado en repositorios públicos una gran cantidad de datos de proteómica obtenidos a partir de muestras de CCR, esta información no ha sido tan utilizada como en el caso de transcriptómica. Esto es principalmente debido a la dificultad en la integración de los datos y a la menor anotación de las muestras en los repositorios. En esta Tesis Doctoral, se realizó un metaestudio incluyendo datasets públicos que contenían muestras de biopsias sólidas y biopsias líquidas. Esto permitió desarrollar un mapa de expresión proteica en muestras de CCR que permite comparar la expresión proteica entre tejido sano y tumor, evaluar la asociación con pronóstico y examinar una potencial detección en biopsias líquidas. Este metaestudio se aplicó en la validación y descubrimiento de biomarcadores, confirmando el potencial de SEC6 a nivel de proteína e identificando cinco nuevos biomarcadores pronósticos potencialmente detectables en suero (CD14, MRC2, PPIA, PRDX1 y TXNDC5). En conclusión, en esta Tesis Doctoral se abordan dos áreas de gran interés en el estudio del cáncer: la inhibición de la metástasis y el descubrimiento de nuevos biomarcadores pronósticos. En lo respectivo a la metástasis, se demostró el potencial de CDH6 como diana antimetastásica en cáncer de ovario y de riñón. Además, se reforzó la evidencia de la implicación clave de CDH17 en metástasis hepática de CCR. En el campo de los biomarcadores, se desarrolló y validó la firma pronóstica SEC6 y se realizó un metaestudio a partir de datasets públicos de proteómica con aplicación en el descubrimiento y validación de biomarcadores., Esta Tesis doctoral fue financiada por los proyectos RTI2018-095055-B-100 y PID2021-122227OB-I00 del MICYT, así como el doctorado industrial IND2019/BMD-17153 de la Comunidad de Madrid y la plataforma PRB3 (ISCIII-SGEFI/FEDER-PT17/0019/0008) del ISCIII., Peer reviewed, Modelo experimental alternativo-NAM, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Molecular mechanisms and therapeutic applications of interleukin-13 receptor α2 and cadherin-6 in cancer progression, Mecanismos moleculares y aplicaciones terapéuticas del receptor a2 de la interleukina 13 y cadherina 6 en progresión tumoral

  • Martín Regalado, Angela
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología. Fecha de Lectura: 18-06-2024. Programa de Doctorado en Biología, [EN] According to the World Health Organization, cancer is the second cause of death worldwide before the age of 70, only surpassed by cardiovascular disease. In 2020, 19.3 million new cancer cases and almost 10 million cancer-related deaths were reported globally. On one hand, glioblastoma (GBM) is the most common malignant primary brain tumor in adults, with an incident of 3 to 4 cases out of 100,000 people. The median overall survival for patients is between 15 and 16 months, and the 5-year survival falls around 7.2%. On the other hand, metastasis, defined as the growth of cancer cells in different organs from the one where the cancer originated, is the final step of cancer. It is estimated that around 90% of cancer-related deaths are directly related to metastatic disease. The huge heterogeneity of cancer, together with the dismal prognosis of GBM and metastatic tumors, raises the necessity of novel therapeutic options that lead to an increase in the survival of cancer patients. Previous results reported by our group highlighted the importance of interleukin-13 (IL-13) signaling through IL-13 receptor α2 (IL13Rα2) to promote colorectal cancer (CRC) metastasis. Likewise, we demonstrated the ability of therapeutic peptides (D1 peptide) and monoclonal antibodies (mAbs) (5.5.4 and 4.4.2) to specifically target IL-13/IL13Rα2 pathway and prevent metastasis. On the other hand, our group described the role of cadherin-17 (CDH17) and cadherin-5 (CDH5), that contain an RGD motif, in breast cancer and melanoma metastasis, and the ability of the anti-RGD 6.6.1 mAb to prevent metastasis. We also described the role of cadherin-6 (CDH6) to regulate α2β1 integrin-mediated adhesion and invasion in ovarian and renal cancer. Therefore, the main objective of this Doctoral Thesis was to investigate the role of IL13Rα2, CDH6 and their related proteins in GBM and metastatic tumors to decipher their molecular mechanisms and find novel molecular targets with therapeutic potential. First, we demonstrated the value of inhibiting IL-13/IL13Rα2 signaling using D1 peptide and 5.5.4 mAb. The use of these therapeutic molecules inhibited IL-13/IL13Rα2-mediated metastatic capacities and activation of downstream mediators in cancer cells. In addition, 5.5.4 mAb increased the survival of mice with lung cancer. In collaboration with Protein Alternatives SL, we generated the recombinant versions of 5.5.4 and 4.4.2 mAbs (traditionally generated by hybridoma production) and tested their efficacy in vitro and in vivo. To delve deeper into the IL-13/IL13Rα2 pathway, we investigated the interaction network of IL13Rα2 using two different approaches: immunoprecipitation (IP) and proximity-dependent biotin identification (BioID). Using these techniques, we found PTP1B as a relevant IL13Rα2 interactor and deciphered the specific site by which IL13Rα2 binds to PTP1B. We demonstrated the role of PTP1B within the IL-13/IL13Rα2 signaling pathway, as PTP1B inhibition reduced IL-13/IL13Rα2-mediated metastatic capacities and activation of downstream mediators (FAK, Src, AKT and ERK1/2). Using claramine, a well-done PTP1B specific inhibitor, we mimicked the effects of PTP1B silencing over IL-13/IL13Rα2-induced metastatic capacities. In vivo, claramine completely protected mice from CRC liver metastasis and significantly extended lifespan of GBM-bearing mice. Given the importance of PTP1B as IL13Rα2 interactor and therapeutic target, we followed the same strategy and studied the PTP1B protein interaction network using IP and BioID and found a relevant involvement of PTP1B interactors in the NF-κB pathway., [EN] Then, we investigated the phosphorylation changes caused by IL-13 treatment through PTP1B signaling. We demonstrated that phosphorylation changes in SHN3, a transcription factor that can bind to κB motifs in the DNA, are executed by the action of a specific kinase, CSKN2, in response to IL-13 signaling through PTP1B. We identified SHN3 as a downstream mediator of IL-13/IL13Rα2/PTP1B pathway that plays a crucial role in the interplay between Wnt and NF-κB signaling pathways in cancer cells that express IL13Rα2. SHN3 regulates tumor growth in IL13Rα2-positive cancer cells and correlates with lower prognosis in different types of human cancers. Our data have uncovered a great part of the IL-13/IL13Rα2/PTP1B signaling pathway and provided a link between the IL-13/PTP1B/Src pathway and the already described IL-13/AP-1 pathway. Then, in collaboration with the research group of Irina V Balyasnikova (Northwestern University), we aimed to modulate the surface expression of IL13Rα2 to enhance the efficacy of bi-specific T cell engagers (BiTEs) highly specific to IL13Rα2. We demonstrated the ability of histone deacetylase inhibitors (HDACi) to modulate the expression of IL13Rα2 in the surface of glioma cells. Treatment of glioma cells with panobinostat and romidepsin, the most efficient compounds tested, increased the efficiency of T cells to kill glioma cells in the presence of BiTE, as well as T cell activation. On the other hand, we studied the role of CDH6 in omental and bone metastasis, as CDH6 is highly expressed in ovarian and renal cancers and is involved in bone metastasis development. We generated CDH6-stably silenced ovarian carcinoma cells and observed a decrease in the metastatic capacities in vitro and a reduced homing capacity to mouse liver and lungs, as well as in the activation of Wnt pathway. However, we observed an increased capacity of CDH6-silenced cells to perform omental metastasis. Using 6.6.1 mAb in two different bone metastasis mouse models, we demonstrated its capacity to decrease the development of bone metastasis and increase mice survival. Finally, we investigated the transcriptional changes caused by CDH6 silencing in ovarian cancer cells and found the involvement of the dysregulated genes in the epithelial to mesenchymal transition (EMT), KRAS signaling, hypoxia and apoptosis, among other functions. We investigated the SPANX family of genes, that was found to be very downregulated in the CDH6-silenced cells. Silencing of SPANXB1, the most downregulated gene among the SPANX family, hindered the metastatic capacities of ovarian carcinoma cells both in vitro and in vivo. We observed that SPANXB1 behavior was like others stem cell markers, suggesting a regulatory loop between cadherins and stemness factors. In conclusion, this Doctoral Thesis describes novel molecular mechanisms and therapeutic applications to target GBM and metastatic cancers. We have uncovered a great part of IL 13/IL13Rα2 signaling pathway and demonstrated the therapeutic value of IL13Rα2, PTP1B and SHN3. We have provided a very relevant link between IL13Rα2 and important oncogenic pathways, such as Wnt/β-catenin, NF-κB and MMP9. We have contributed to describe the role of CDH6 in omental and bone metastasis and proposed SPANX protein family as a novel therapeutic target., Ángela Martín-Regalado recibió el apoyo de una beca FPU (FPU 18/05766-MEFP). Esta Tesis Doctoral fue financiada por el proyecto RTI2018-095055-B-100 del MICYT y los proyectos PID2021-122227OB-I00 y CPP2021-008337 del MCIN/AEI/10.13039/501100011033 utilizando fondos de Next Generation EU/PRTR., Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Tipos celulares - líneas celulares primarias